These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15886162)

  • 1. Encouraging the development of new vaccines.
    Grabowski H
    Health Aff (Millwood); 2005; 24(3):697-700. PubMed ID: 15886162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan drug development in the United States.
    Groft SC
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.
    Kettler HE; Modi R
    Bull World Health Organ; 2001; 79(8):742-7. PubMed ID: 11545331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting U.S. manufacturers' decisions to produce vaccines.
    Coleman MS; Sangrujee N; Zhou F; Chu S
    Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In defence of priority review vouchers.
    Sonderholm J
    Bioethics; 2009 Sep; 23(7):413-20. PubMed ID: 19659848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 10. Incentives for biodefense countermeasure development.
    Matheny J; Mair M; Mulcahy A; Smith BT
    Biosecur Bioterror; 2007 Sep; 5(3):228-38. PubMed ID: 17903091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming economic barriers to the optimal use of vaccines.
    Lieu TA; McGuire TG; Hinman AR
    Health Aff (Millwood); 2005; 24(3):666-79. PubMed ID: 15886158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening the supply of routinely administered vaccines in the United States: problems and proposed solutions.
    Klein JO; Myers MG
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S97-103. PubMed ID: 16447139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why sole-supplier vaccine markets may be here to stay.
    Danzon P; Pereira NS
    Health Aff (Millwood); 2005; 24(3):694-6. PubMed ID: 15886161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.
    Towse A; Kettler H
    Bull World Health Organ; 2005 Apr; 83(4):301-7. PubMed ID: 15868022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving vaccine supply and development: who needs what?
    Pauly MV
    Health Aff (Millwood); 2005; 24(3):680-9. PubMed ID: 15886159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost/success projections for US biodefense countermeasure development.
    Matheny J; Mair M; Smith B
    Nat Biotechnol; 2008 Sep; 26(9):981-3. PubMed ID: 18779804
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 20. Keys to strengthening the supply of routinely recommended vaccines: view from industry.
    Pisano W
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S111-7. PubMed ID: 16447131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.